ArticleBMJ oncology2025
Identification of protein biomarker candidates associated with organ-specific immune-related toxicity and response to management by plasma proteomics.
Article in BMJ oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Immune-related adverse events (irAEs) are a growing challenge with checkpoint inhibitors (CPIs) and are complicated by the lack of suitable response biomarkers in many irAEs. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) based proteomics is a system-wide unbiased analysis method suited for biomarker discovery. In this study, plasma samples from patients suffering from irAEs were analysed using MS-based proteomics. Methods and analysis: The discovery cohort consisted of 37 melanoma patients experiencing an irAE (colitis, hepatitis and nephritis) collected around irAE management. The validation cohort consisted of 34 irAE patients (colitis, hepatitis, nephritis and pneumonitis) at management, with a control group consisting of 34 patients treated with CPIs without an irAE. The plasma samples were processed with bottom-up proteomics and analysed on an Orbitrap Astral Mass Spectrometer with short LC gradients. Results: During an irAE, we found upregulation of multiple acute-phase protein reactants. The level of these was higher in patients in combination CPI therapy-also observed in the control cohort without irAE. We found multiple hepatic proteins associated with immune-related hepatitis, including fructose-biphosphate aldolase B (ALDOB), showing the widest dynamic range. Further, we found a correlation of lipocalin-2/neutrophil gelatinase-associated lipocalin (LCN2/NGAL) to nephritis and colitis with a significant correlation to the clinical toxicity grade confirmed by an immunoassay. Finally, high levels of angiotensinogen (AGT), chitinase-3-like protein 1 (CHI3L1) and lectin mannose-binding 2 (LMAN2) showed a significant association with poor prednisolone response. Conclusion: In conclusion, using LC-MS/MS-based plasma proteomics, we identified several irAE-related biomarker candidates to be further assessed for toxicity grading and management in the context of monitoring irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.